Kumar Priyanka, Benjamin David J, Darabi Sourat, Kloecker Goetz, Rezazadeh Kalebasty Arash
Department of Hematology and Medical Oncology, Harbor-UCLA Medical Center, Torrance, CA 90502, United States.
Department of Medical Oncology, Hoag Family Cancer Institute, Newport Beach, CA 92663, United States.
World J Clin Oncol. 2024 Aug 24;15(8):975-981. doi: 10.5306/wjco.v15.i8.975.
Recent advancements in next generation sequencing have allowed for genetic information become more readily available in the clinical setting for those affected by cancer and by treating clinicians. Given the lack of access to geneticists, medical oncologists and other treating physicians have begun ordering and interpreting genetic tests for individuals with cancer through the process of "mainstreaming". While this process has allowed for quicker access to genetic tests, the process of "mainstreaming" has also brought several challenges including the dissemination of variants of unknown significance results, ordering of appropriate tests, and accurate interpretation of genetic results with appropriate follow-up testing and interventions. In this editorial, we seek to explore the process of informed consent of individuals before obtaining genetic testing and offer potential solutions to optimize the informed consent process including categorization of results as well as a layered consent model.
下一代测序技术的最新进展使癌症患者及其治疗临床医生能够在临床环境中更轻松地获取遗传信息。由于缺乏遗传学家，医学肿瘤学家和其他治疗医生已开始通过“主流化”过程为癌症患者订购和解读基因检测。虽然这一过程使人们能够更快地进行基因检测，但“主流化”过程也带来了一些挑战，包括意义未明变异结果的传播、适当检测的订购以及通过适当的后续检测和干预对基因结果进行准确解读。在这篇社论中，我们试图探讨在进行基因检测之前个体的知情同意过程，并提供优化知情同意过程的潜在解决方案，包括结果分类以及分层同意模型。
